Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
PACB > SEC Filings for PACB > Form 8-K on 24-Jul-2014All Recent SEC Filings




Results of Operations and Financial Condition, Financial

Item 2.02.Results of Operations and Financial Condition.

This current report on Form 8-K contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are based on management's beliefs and assumptions and on information currently available to them. The Company's actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks faced by us and described in the Company's most recently filed Quarterly Report on Form 10-Q, Annual Report on Form 10-K, or the Company's other filings with the SEC, as the case may be. You should not place undue reliance on forward-looking statements, which apply only as of the date of this Current Report on Form 8-K. The Company assumes no obligation to update these forward-looking statements.

On July 24, 2014, Pacific Biosciences of California, Inc. (the "Company") reported its financial results for the quarter ended June 30, 2014. The Company's unaudited Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Operations and Comprehensive Loss and Condensed Consolidated Statements of Cash Flows are included as Exhibits 99.1, 99.2 and 99.3 hereto, respectively, and are incorporated herein by reference.

Revenue for the second quarter of 2014 totaled $11.4 million, compared to $6.0 million for the second quarter of 2013. Second quarter 2014 revenue reflects the delivery of eight PacBio RS II systems, compared to three systems during the second quarter of 2013. Total revenue for the second quarter of 2014 also included $1.7 million of contractual revenue. The Company expects 2014 revenue to exceed that recognized during 2013; however, revenue may fluctuate quarter to quarter.

As of June 30, 2014, the Company's instrument backlog was comprised of 10 instruments.

Gross profit for the second quarter of 2014 increased 195% to $3.1 million, compared to a gross profit of $1.1 million for the same period of 2013. The increase in gross profit from 2013 to 2014 primarily reflects the gross profit realized in 2014 relating to increases in contractual revenue. Gross margin for the second quarter of 2014 was 27.4% compared to 17.5% for the same period during 2013. Gross margin increased primarily due to the increase in contractual revenue partially offset by changes in product mix. Gross margin for the remainder of this year is expected to remain near current levels, subject to fluctuation on a quarterly basis due to the mix of instruments and consumables delivered each quarter and the geographies into which the products are sold.

Operating expenses totaled $21.4 million for the quarter ended June 30, 2014 compared to $21.1 million for the quarter ended June 30, 2013. Operating expenses for the second quarter of 2014 and 2013 included non-cash stock-based compensation of $2.1 million and $2.3 million, respectively. The Company anticipates quarterly operating expenses to remain near current levels for the remainder of 2014.

Cash and investments at June 30, 2014 totaled $105.0 million, compared to $112.5 million at December 31, 2013. During the six-month period ended June 30, 2014, the Company received $20.6 million through the sale of common stock under its current "at-the-market" offering program. Excluding proceeds from the "at-the-market" offering, cash and investments decreased by $28.1 million compared to December 31, 2013, primarily reflecting $29.9 million of cash used in operating activities and $0.9 million of fixed asset purchases partially offset by $2.7 million of proceeds received from equity sales through the Company's employee equity plans.

The information set forth in this Item 2.02, as well as Exhibit 99.1, 99.2 and 99.3 referenced therein, shall be deemed "filed" for purposes of the Securities Exchange Act of 1934, as amended, and shall be incorporated by reference into the Company's filings under the Securities Act of 1933, as amended.


(d) Exhibits.

99.1   Condensed Consolidated Balance Sheets (unaudited)
99.2   Condensed Consolidated Statements of Operations and Comprehensive Loss
99.3   Condensed Consolidated Statements of Cash Flows (unaudited)

  Add PACB to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for PACB - All Recent SEC Filings
Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.